Trust Co. of Vermont trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 9.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,943 shares of the company’s stock after selling 1,205 shares during the period. Trust Co. of Vermont’s holdings in Novo Nordisk A/S were worth $625,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the business. Camarda Financial Advisors LLC purchased a new position in Novo Nordisk A/S during the first quarter valued at approximately $28,000. Bruderman Asset Management LLC purchased a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. WP Advisors LLC purchased a new position in Novo Nordisk A/S during the first quarter valued at approximately $39,000. Pinnacle Bank purchased a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $40,000. Finally, Quantamental Technologies LLC bought a new stake in Novo Nordisk A/S in the first quarter worth approximately $41,000. 7.15% of the stock is owned by hedge funds and other institutional investors.
Shares of NVO traded down $0.91 during trading hours on Wednesday, hitting $47.03. The stock had a trading volume of 877,548 shares, compared to its average volume of 1,328,136. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.66 and a current ratio of 0.96. Novo Nordisk A/S has a 52 week low of $41.23 and a 52 week high of $52.83. The firm has a market cap of $118.73 billion, a price-to-earnings ratio of 18.66, a PEG ratio of 2.20 and a beta of 0.56.
Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Friday, May 3rd. The company reported $0.66 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.04. Novo Nordisk A/S had a net margin of 33.60% and a return on equity of 78.28%. The business had revenue of $4.46 billion for the quarter, compared to analyst estimates of $4.35 billion. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 2.43 EPS for the current fiscal year.
Several analysts have commented on the stock. Zacks Investment Research downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Wednesday, February 13th. Pareto Securities cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Credit Suisse Group upgraded shares of Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Monday, April 29th. BNP Paribas started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 29th. They issued an “outperform” rating for the company. Finally, Barclays restated a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 5th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the stock. Novo Nordisk A/S presently has a consensus rating of “Hold” and an average price target of $52.31.
ILLEGAL ACTIVITY WARNING: “Trust Co. of Vermont Decreases Stake in Novo Nordisk A/S (NVO)” was published by Sundance Herald and is the property of of Sundance Herald. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://sundanceherald.com/2019/05/29/trust-co-of-vermont-sells-1205-shares-of-novo-nordisk-a-s-nvo.html.
Novo Nordisk A/S Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.